MY114610A - Controlled drug delivery system for diltiazem. - Google Patents

Controlled drug delivery system for diltiazem.

Info

Publication number
MY114610A
MY114610A MYPI98005480A MYPI19985480A MY114610A MY 114610 A MY114610 A MY 114610A MY PI98005480 A MYPI98005480 A MY PI98005480A MY PI19985480 A MYPI19985480 A MY PI19985480A MY 114610 A MY114610 A MY 114610A
Authority
MY
Malaysia
Prior art keywords
diltiazem
weight
polymer
delivery system
drug delivery
Prior art date
Application number
MYPI98005480A
Inventor
Nagaprasad V
Sen Himadri
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/984,733 external-priority patent/US6074669A/en
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of MY114610A publication Critical patent/MY114610A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET OR A CAPSULE FOR THE CONTROLLED RELEASE OF DILTIAZEM, COMPRISES ABOUT 30 TO ABOUT 97BY WEIGHT OF A HYDROPHILIC POLYMER, ABOUT 0.5 TO ABOUT 30BY WEIGHT OF AN ENTERIC (PH-DEPENDENT) POLYMER, AND ABOUT 2.5 TO ABOUT 60BY WEIGHT OF DILTIAZEM OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF. THE RATIO OF HYDROPHILIC POLYMER TO ENTERIC POLYMER IS IN THE RANGE OF ABOUT 1:1 TO ABOUT 15:1. SUCH A PHARMACEUTICAL COMPOSITION RELEASES DILTIAZEM AT A RATE THAT ALLOWS EFFECTIVE PLASMA LEVELS OF DILTIAZEM TO BE MAINTAINED OVER A PERIOD OF TWENTY-FOUR HOURS AFTER ADMINISTRATION TO HUMAN ADULT SUBJECTS. FIGURE 1
MYPI98005480A 1997-12-04 1998-12-03 Controlled drug delivery system for diltiazem. MY114610A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/984,733 US6074669A (en) 1997-01-20 1997-12-04 Controlled drug delivery system for diltiazem

Publications (1)

Publication Number Publication Date
MY114610A true MY114610A (en) 2002-11-30

Family

ID=25530809

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98005480A MY114610A (en) 1997-12-04 1998-12-03 Controlled drug delivery system for diltiazem.

Country Status (4)

Country Link
CN (1) CN1166364C (en)
AU (1) AU9521398A (en)
MY (1) MY114610A (en)
SG (1) SG74102A1 (en)

Also Published As

Publication number Publication date
AU9521398A (en) 1999-06-24
SG74102A1 (en) 2000-07-18
CN1237417A (en) 1999-12-08
CN1166364C (en) 2004-09-15

Similar Documents

Publication Publication Date Title
MY125662A (en) Pharmaceutical formulations containing darifenacin
NZ508526A (en) Opioid formulations for treating pain
MX9804008A (en) Pharmaceutical formulations.
DE69816951D1 (en) Preparation containing cefaclor or cephalexin with a modified release matrix
GR3033325T3 (en) Controlled release preparation containing a salt of morphine.
IL109770A0 (en) Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
UA41995C2 (en) PHARMACEUTICAL FORM OF AZITROMYCIN WITH CONTROLLED RELEASE (OPTIONS), METHOD OF ITS INTRODUCTION, METHOD OF ITS MANUFACTURE AND METHOD OF TREATMENT
CA2025703A1 (en) Pulsatile once-a-day delivery systems for minocycline
AU5895596A (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
IL209703A0 (en) Controlled release hydrocodone formulations
PL324402A1 (en) Preparation of controllable release of slightly coluble drugs contained therein
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
NO962752L (en) Use of 2,3-diaryl-1-benzopyran derivatives in the manufacture of a medicament for the treatment and prevention of bone loss and osteoporosis
PL317996A1 (en) Carbamazepinic form of a drug with retarded release of biologically active substance
DE69634080D1 (en) MEANS OF PREVENTING THE TURNING OF THE FRONT LENS CAPSULE
MY114610A (en) Controlled drug delivery system for diltiazem.
EP0649660A3 (en) Pharmaceutical composition for parenteral, enteral and dermal administration of essentially insoluble drugs and process for their preparation.
CA2356306A1 (en) Sulfated phosphatidylinositols, their preparation and use
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
MY110769A (en) Controlled release oxycodone compositions.
TH52205A (en) Controlled drug delivery system for diltiazem